Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs OneSpan Inc (OSPN) Price & Performance

Amylx Pharmaceuticals IncTrade
OneSpan IncTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs OneSpan Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.58 (market cap $2.64B), while OneSpan Inc trades at $16.3 (market cap $600.69M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 4.4× OneSpan Inc's market cap, and OneSpan Inc pays a 3.19% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXOSPN
Market Cap
$2.64B$600.69M
Sector
HealthTechnology
52-Week High
$24.19$16.78
52-Week Low
$7.82$10.15
Enterprise Value
$2.39B$569.77M
Dividend Yield
3.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.

The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.

OneSpan Inc

OneSpan (OSPN) trades at $16.17, down 1.22% today, with strong fundamental metrics including a P/E of 9.21 and net income margin of 27.76%. The stock shows bullish technical signals with recent earnings beats and analyst consensus pointing to upside potential. Recent product launches like DigipassONE demonstrate ongoing innovation in authentication solutions.

The outlook remains positive with 67% analyst buy ratings and a $17.00 consensus target. Risks include declining operating cash flow and competitive pressure in the software security space. The stock offers value characteristics with reasonable valuation multiples and consistent dividend payments.

Returns comparison

Trailing returns across standard periods

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About OneSpan Inc

OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.

Read more on OSPN